Paolo Gontero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7044106/publications.pdf

Version: 2024-02-01

277 papers 11,923 citations

52 h-index 99 g-index

284 all docs 284 docs citations

times ranked

284

10379 citing authors

#	Article	IF	Citations
1	Loopâ€tail stents fail in reducing stentâ€related symptoms: results of a prospective randomised controlled trial. BJU International, 2022, 129, 123-129.	2.5	9
2	Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups. European Urology, 2022, 81, 193-203.	1.9	30
3	An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer. Journal of Urology, 2022, 207, 350-357.	0.4	13
4	European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and) Tj ETQq0 0 (0 rgBT /Ov	erlock 10 Tf 5
5	COVID-19 pandemic impact on uro-oncological disease outcomes at an Italian tertiary referral center. World Journal of Urology, 2022, 40, 263-269.	2.2	6
6	The Outcomes of Glansectomy and Split Thickness Skin Graft Reconstruction for Invasive Penile Cancer Confined to Glans. Urology, 2022, 165, 250-255.	1.0	2
7	Segmental Ureterectomy Versus Radical Nephroureterectomy in Older Patients Treated for Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, , .	1.9	3
8	Awake Da Vinci robotic partial nephrectomy: First case report ever in a situation of need. Urology Case Reports, 2022, 42, 102008.	0.3	3
9	mEPE-score: a comprehensive grading system for predicting pathologic extraprostatic extension of prostate cancer at multiparametric magnetic resonance imaging. European Radiology, 2022, 32, 4942-4953.	4.5	7
10	Prognostic impact of insulinâ€like growth factorâ€l and its binding proteins, insulinâ€like growth factorâ€l binding proteinâ€2 and â€3, on adverse histopathological features and survival outcomes after radical cystectomy. International Journal of Urology, 2022, , .	1.0	3
11	Machine Learning-Based Prediction of Pathological Upgrade From Combined Transperineal Systematic and MRI-Targeted Prostate Biopsy to Final Pathology: A Multicenter Retrospective Study. Frontiers in Oncology, 2022, 12, 785684.	2.8	1
12	Outcomes of Salvage Radical Prostatectomy for MO Castration-resistant Recurrent Prostate Cancer: A Reasonable Option in the Era of New Antiandrogen Therapies?. European Urology Focus, 2021, 7, 807-811.	3.1	2
13	Toward Individualized Approaches to Partial Nephrectomy: Assessing the Correlation Between Ischemia Time and Patient Health Status (RECORD2 Project). European Urology Oncology, 2021, 4, 645-650.	5 . 4	13
14	Suprapubic pedicled phalloplasty in transgender men: a multicentric retrospective cohort analysis. International Journal of Impotence Research, 2021, 33, 808-814.	1.8	14
15	Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases. BJU International, 2021, 127, 122-130.	2.5	36
16	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. European Urology, 2021, 79, 62-79.	1.9	532
17	Making a case "against―focal therapy for intermediate-risk prostate cancer. World Journal of Urology, 2021, 39, 719-728.	2.2	7
18	How radical prostatectomy procedures have changed over the last 10Âyears in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. World Journal of Urology, 2021, 39, 1445-1452.	2.2	0

#	Article	IF	CITATIONS
19	Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassifications. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 296.e1-296.e9.	1.6	2
20	Indications for and complications of pelvic lymph node dissection in prostate cancer: accuracy of available nomograms for the prediction of lymph node invasion. BJU International, 2021, 127, 318-325.	2.5	28
21	Perioperative Outcomes of Open, Laparoscopic, and Robotic Partial Nephrectomy: A Prospective Multicenter Observational Study (The RECORd 2 Project). European Urology Focus, 2021, 7, 390-396.	3.1	63
22	The Frontier of Penile Implants in Phalloplasty: Is the ZSI 475 FTM what we have been waiting for?. International Journal of Impotence Research, 2021, 33, 779-783.	1.8	7
23	Natural history of widespread high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: should we rebiopsy them all?. Scandinavian Journal of Urology, 2021, 55, 129-134.	1.0	4
24	How uro-oncology has been affected by COVID-19 emergency? Data from Piedmont/Valle d'Aosta Oncological Network, Italy. Urologia, 2021, 88, 3-8.	0.7	10
25	Ejaculation-sparing versus non-ejaculation-sparing anatomic GreenLight laser enucleo-vaporization of the prostate: first comparative study. World Journal of Urology, 2021, 39, 3455-3463.	2.2	3
26	Association of patients' sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer. World Journal of Urology, 2021, 39, 3337-3344.	2.2	9
27	Recipient pre-existing chronic hypotension is associated with delayed graft function and inferior graft survival in kidney transplantation from elderly donors. PLoS ONE, 2021, 16, e0249552.	2.5	8
28	European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. European Urology, 2021, 79, 480-488.	1.9	198
29	MRI index lesion radiomics and machine learning for detection of extraprostatic extension of disease: a multicenter study. European Radiology, 2021, 31, 7575-7583.	4.5	40
30	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non–muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non–muscle-invasive Bladder Cancer Guidelines Panel Study. European Urology Oncology, 2021, 4, 182-191.	5.4	54
31	Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 296.e21-296.e29.	1.6	24
32	Functional and Patient Reported Outcomes Following Total Glans Resurfacing. Journal of Sexual Medicine, 2021, 18, 1099-1103.	0.6	7
33	Outcomes and Cost Evaluation Related to a Single-Use, Disposable Ureteric Stent Removal System: a Systematic Review of the Literature. Current Urology Reports, 2021, 22, 41.	2.2	2
34	Surgical Outcomes of Glansectomy and Split Thickness Skin Graft Reconstruction for Localized Penile Cancer. Urology, 2021, 152, 195.	1.0	4
35	100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19. Nature Reviews Urology, 2021, 18, 611-622.	3.8	80
36	Low Levels of Urinary PSA Better Identify Prostate Cancer Patients. Cancers, 2021, 13, 3570.	3.7	9

#	Article	IF	CITATIONS
37	Pigtail Suture Stents Significantly Reduce Stent-related Symptoms Compared to Conventional Double J Stents: A Prospective Randomized Trial. European Urology Open Science, 2021, 29, 1-9.	0.4	25
38	Reply to Eugenio Ventimiglia, Oliver Wiseman, and Olivier Traxer's Letter to the Editor re: Andrea Bosio, Eugenio Alessandria, Simone Agosti, et al. Pigtail Suture Stents Significantly Reduce Stent-related Symptoms Compared to Conventional Double J Stents: A Prospective Randomized Trial. Eur Urol Open Sci 2021;29:1–9. European Urology Open Science, 2021, 31, 47-48.	0.4	0
39	Reply to letter by Montorsi etÂal. Re: Marra etÂal. â€~Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'. BJU International, 2021, 128, 524-524.	2.5	0
40	The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis. Cancers, 2021, 13, 5276.	3.7	21
41	Clinical outcomes and temporal trends of immunological and non-immunological rare diseases in adult kidney transplant. BMC Nephrology, 2021, 22, 386.	1.8	1
42	Risk Stratification Tools and Prognostic Models in Non–muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. European Urology Focus, 2020, 6, 479-489.	3.1	72
43	Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 77.e1-77.e7.	1.6	26
44	An outcomes analysis of penile prosthesis implantation following radical cystoprostatectomy and urinary diversion: a multicentric retrospective cohort study. International Journal of Impotence Research, 2020, 32, 126-132.	1.8	7
45	Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2020, 18, 20-25.e2.	1.9	18
46	Total Glans Resurfacing for the Management of Superficial Penile Cancer: A Retrospective Cohort Analysis in a Tertiary Referral Center. Urology, 2020, 145, 281-286.	1.0	11
47	Reply to Comment on "Suprapubic Pedicled Phalloplasty in Transgender Men: a Multicentric Retrospective Cohort Analysis― International Journal of Impotence Research, 2020, , .	1.8	0
48	Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging–targeted Biopsy. European Urology Oncology, 2020, 3, 739-747.	5.4	31
49	Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. European Urology Oncology, 2020, 3, 565-581.	5.4	46
50	External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter study. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 847.e9-847.e16.	1.6	11
51	Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer. Current Opinion in Urology, 2020, 30, 542-546.	1.8	6
52	Small Non-Coding RNA Profiling in Plasma Extracellular Vesicles of Bladder Cancer Patients by Next-Generation Sequencing: Expression Levels of miR-126-3p and piR-5936 Increase with Higher Histologic Grades. Cancers, 2020, 12, 1507.	3.7	33
53	AUTHOR REPLY. Urology, 2020, 140, 131.	1.0	0
54	Stratification of Intermediate-risk Non–muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies. European Urology Focus, 2020, 7, 566-573.	3.1	14

#	Article	IF	Citations
55	Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation. European Radiology, 2020, 30, 6274-6284.	4.5	22
56	Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis. Frontiers in Oncology, 2020, 10, 246.	2.8	11
57	The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancerâ€specific survival after radical cystectomy: external validation in a large biâ€institutional cohort. BJU International, 2020, 126, 704-714.	2.5	7
58	Long-Term Surgical, Functional, and Patient Reported Outcomes of a Modified Corporoplasty: A Tertiary Referral Center Experience. Journal of Sexual Medicine, 2020, 17, 1779-1786.	0.6	0
59	Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 602.e11-602.e19.	1.6	11
60	Transperineal Free-hand mpMRI Fusion-targeted Biopsies Under Local Anesthesia: Technique and Feasibility From a Single-center Prospective Study. Urology, 2020, 140, 122-131.	1.0	21
61	The Impact of COVID-19 Outbreak on Uro-oncological Practice Across Europe: Which Burden of Activity Are We Facing Ahead?. European Urology, 2020, 78, 124-126.	1.9	32
62	External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. European Urology, 2020, 78, 138-142.	1.9	55
63	Transurethral resection of bladder tumor and the need for re-transurethral resection of bladder tumor. Current Opinion in Urology, 2020, 30, 370-376.	1.8	5
64	Comment on: "Masculinizing genital gender-affirming surgery: metoidioplasty and urethral lengthening― International Journal of Impotence Research, 2020, , .	1.8	1
65	Segmental ureterectomy vs. radical nephroureterectomy for ureteral carcinoma in patients with a preoperative glomerular filtration rate less than 90 ml/min/1.73 m2: A multicenter study. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 601.e11-601.e16.	1.6	6
66	Ex vivo bench flexible ureterorenoscopy in the diagnosis and treatment of renal stones in deceasedâ€donor kidneys: the first case series. Transplant International, 2020, 33, 958-960.	1.6	1
67	Pain in Men Undergoing Transperineal Free-Hand Multiparametric Magnetic Resonance Imaging Fusion Targeted Biopsies under Local Anesthesia: Outcomes and Predictors from a Multicenter Study of 1,008 Patients. Journal of Urology, 2020, 204, 1209-1215.	0.4	17
68	How bothersome double-J ureteral stents are after semirigid and flexible ureteroscopy: a prospective single-institution observational study. World Journal of Urology, 2019, 37, 201-207.	2.2	30
69	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and) Tj ETQq1 1 0.784	1314 rgBT 1.9	/Oygrlock 1
70	How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?. European Urology Oncology, 2019, 4, 663-669.	5.4	1
71	Complications, oncological and functional outcomes of salvage treatment options following focal therapy for localized prostate cancer: a systematic review and a comprehensive narrative review. World Journal of Urology, 2019, 37, 1517-1534.	2.2	20
72	Segmental resection of distal ureter with terminoâ€terminal ureteric anastomosis vs bladder cuff removal and ureteric reâ€implantation for upper tract urothelial carcinoma: results of a multicentre study. BJU International, 2019, 124, 116-123.	2.5	8

#	Article	IF	Citations
73	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. European Journal of Surgical Oncology, 2019, 45, 1983-1992.	1.0	18
74	Drug strategies for bladder cancer in the elderly: is there promise for the future? Expert Opinion on Pharmacotherapy, 2019, 20, 1387-1396.	1.8	1
75	The impact of warmed and humidified CO ₂ insufflation during robotic radical prostatectomy: Results of a randomized controlled trial. Urologia, 2019, 86, 130-140.	0.7	6
76	Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 430-436.	1.6	50
77	Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review. World Journal of Urology, 2019, 37, 1469-1483.	2.2	23
78	Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?. Translational Andrology and Urology, 2019, 8, 85-93.	1.4	14
79	The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer. Translational Andrology and Urology, 2019, 8, 46-53.	1.4	22
80	Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). Abdominal Radiology, 2019, 44, 1883-1893.	2.1	80
81	Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, Pl3K/Akt, GSK- $3\hat{l}^2$ signaling and inhibition of cellular prostatic acid phosphatase. Cancer Letters, 2019, 449, 252-262.	7.2	19
82	Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. European Urology Oncology, 2019, 2, 456-463.	5.4	13
83	Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection. Carcinogenesis, 2019, 40, 246-253.	2.8	25
84	New insights on occupational exposure and bladder cancer risk: a pooled analysis of two Italian caseâ€"control studies. International Archives of Occupational and Environmental Health, 2019, 92, 347-359.	2.3	4
85	Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non–muscle-invasive Bladder Cancer: Results of a European Survey. European Urology Focus, 2019, 5, 681-688.	3.1	48
86	Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. European Urology Focus, 2019, 5, 205-223.	3.1	103
87	Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016― European Urology Focus, 2019, 5, 457-466.	3.1	112
88	Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non–muscle-invasive Bladder Cancer. European Urology Focus, 2019, 5, 224-241.	3.1	74
89	Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches. Journal of Urology, 2019, 202, 725-731.	0.4	62
90	Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review. European Urology, 2018, 73, 925-933.	1.9	209

#	ARTICLE	IF	Citations
91	Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in nodeâ€positive prostate cancer patients: External validation on a multiâ€institutional database. International Journal of Urology, 2018, 25, 574-581.	1.0	8
92	PD29-04 COMPLICATIONS AND FUNCTIONAL OUTCOMES OF SALVAGE RADICAL PROSTATECTOMY: A COMPARISON BETWEEN OPEN AND ROBOT-ASSISTED APPROACHES IN A MULTICENTRE SERIES Journal of Urology, 2018, 199, .	0.4	0
93	MP11-05 ONCOLOGICAL OUTCOMES OF SALVAGE RADICAL PROSTATECTOMY IN A CONTEMPORARY, MULTICENTRE SERIES OF 395 CASES. Journal of Urology, 2018, 199, .	0.4	0
94	De Novo Bladder Urothelial Neoplasm in Renal Transplant Recipients: A Retrospective, Multicentered Study. Urologia Internationalis, 2018, 100, 185-192.	1.3	10
95	The prognostic value of basal DNA damage level in peripheral blood lymphocytes of patients affected by bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 241.e15-241.e23.	1.6	9
96	Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World Journal of Urology, 2018, 36, 1703-1709.	2.2	71
97	Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy. European Urology Focus, 2018, 4, 288-293.	3.1	7
98	Impact of Microscopic Wall Invasion of the Renal Vein or Inferior Vena Cava on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus: A Multi-institutional Analysis from the International Renal Cell Carcinoma-Venous Thrombus Consortium. European Urology Focus, 2018, 4, 435-441.	3.1	31
99	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. European Urology, 2018, 73, 111-122.	1.9	627
100	Prostate cancer treatment in renal transplant recipients: a systematic review. BJU International, 2018, 121, 327-344.	2.5	26
101	Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Urologic Oncology: Seminars and Original Investigations, 2018, 36, 79.e11-79.e17.	1.6	14
102	How to assess and improve health-related quality of life in bladder cancer patients. Translational Andrology and Urology, 2018, 7, S77-S80.	1.4	4
103	Indication for a Single Postoperative Instillation of Chemotherapy in Non–muscle-invasive Bladder Cancer: What Factors Should Be Considered?. European Urology Focus, 2018, 4, 525-528.	3.1	8
104	Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 529.e11-529.e22.	1.6	31
105	MP48-19 ONCOLOGICAL AND FUNCTIONAL OUTCOMES IN MINIMALLY INVASIVE APPROACH FOR KIDNEY CANCER WITH VENOUS THROMBUS: A MULTICENTRIC STUDY Journal of Urology, 2018, 199, .	0.4	0
106	Accuracy of elastic fusion biopsy in daily practice: Results of a multicenter study of 2115 patients. International Journal of Urology, 2018, 25, 990-997.	1.0	23
107	PD12-10 SURGICAL NOMOGRAM FOR PREDICTING THE LIKELIHOOD OF POSTOPERATIVE SURGICAL COMPLICATIONS IN PATIENTS TREATED WITH PARTIAL NEPHRECTOMY: A PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY (THE RECORD 2 PROJECT). Journal of Urology, 2018, 199, .	0.4	0
108	MP08-10 THE INTRODUCTION OF A SURGICAL CHECKLIST FOR THE TRANSURETHRAL RESECTION OF THE BLADDER IMPROVES RECURRENCE-FREE SURVIVAL IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS. Journal of Urology, 2018, 199, .	0.4	1

#	Article	IF	CITATIONS
109	A Comparative Study Between 2 Different Grafts Used as Patches After Plaque Incision and Inflatable Penile Prosthesis Implantation for End-Stage Peyronie's Disease. Journal of Sexual Medicine, 2018, 15, 848-852.	0.6	29
110	Role of perioperative dynamic sentinel node biopsy for cNO penile cancer management: experience from an Italian tertiary referral center. Tumori, 2018, 104, 66-70.	1.1	4
111	Response and Rebuttal to Editorial Comment "A Comparative Study Between 2 Different Grafts Used as Patches After Plaque Incision and Inflatable Penile Prosthesis Implantation for End-Stage Peyronie's Disease― Journal of Sexual Medicine, 2018, 15, 1061-1062.	0.6	1
112	MMP23B expression and protein levels in blood and urine are associated with bladder cancer. Carcinogenesis, 2018, 39, 1254-1263.	2.8	9
113	Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. European Urology, 2018, 74, 597-608.	1.9	61
114	Is imperative partial nephrectomy feasible for kidney cancer with venous thrombus involvement? Outcomes of 42 cases and matched pair analysis with a large radical nephrectomy cohort. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 339.e1-339.e8.	1.6	9
115	Radiofrequency Ablation for Renal Cancer in Von Hippel–Lindau Syndrome Patients: A Prospective Cohort Analysis. Clinical Genitourinary Cancer, 2018, 16, 28-34.	1.9	14
116	microRNA profiles in urine by next-generation sequencing can stratify bladder cancer subtypes. Oncotarget, 2018, 9, 20658-20669.	1.8	63
117	A Review on the Management of Small Renal Masses: Active Surveillance Versus Surgery. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 940-950.	1.7	6
118	Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results. World Journal of Transplantation, 2018, 8, 178-187.	1.6	14
119	MP78-19 CIGARETTE SMOKING IS ADVERSELY ASSOCIATED WITH PATHOLOGICAL RESPONSE TO PLATINUM-BASED NEOADJUVANT CHEMOTHERAPY IN PATIENTS UNDERGOING TREATMENT FOR URINARY BLADDER CANCER - A PROSPECTIVE EUROPEAN MULTICENTER STUDY OF THE EAU YOUNG ACADEMIC UROLOGISTS (YAU) UROTHELIAL CARCINOMA GROUP, Journal of Urology, 2018, 199, .	0.4	0
120	MP47-20 THE IMPACT OF CIGARETTE SMOKING ON ADVERSE PATHOLOGICAL FEATURES AND SURVIVAL IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER - A PROSPECTIVE, EUROPEAN MULTICENTER STUDY OF THE EAU YOUNG ACADEMIC UROLOGISTS (YAU) UROTHELIAL CARCINOMA GROUP. Journal of Urology, 2018, 199, .	0.4	0
121	MP18-18 SURVIVAL AFTER SEGMENTAL RESECTION OF DISTAL URETER AND TERMINO-TERMINAL URETERAL ANASTOMOSIS VS. BLADDER CUFF REMOVAL AND URETERAL REIMPLANTATION FOR UROTHELIAL CARCINOMA OF THE URETER: RESULTS OF A MULTICENTER STUDY. Journal of Urology, 2018, 199, .	0.4	0
122	Outcome predictors of radical cystectomy in patients with <scp>cT</scp> 4 prostate cancer: a multiâ€institutional study of 62 patients. BJU International, 2017, 120, E52-E58.	2.5	6
123	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non–muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. European Urology, 2017. 72. 801-813.	1.9	205
124	Preoperative anemia is associated with disease recurrence and progression in patients with nonâ€"muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 113.e9-113.e14.	1.6	7
125	Characterization of Late Recurrence After Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. Urology, 2017, 106, 119-124.	1.0	8
126	Increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of bladder cancer. British Journal of Cancer, 2017, 116, 202-210.	6.4	36

#	Article	IF	CITATIONS
127	A Single-center Analysis on the Learning Curve of Male-to-Female Penoscrotal Vaginoplasty by Multiple Surgical Measures. Urology, 2017, 99, 234-239.	1.0	26
128	Robot-Assisted Laparoscopic Pyeloplasty in a Pediatric Patient with Horseshoe Kidney: Surgical Technique and Review of the Literature. Urologia, 2017, 84, 55-60.	0.7	14
129	Treatment of Multiple Synchronous Misdiagnosed Renal Cell Cancers in A Young Patient Affected by A "De Novo―Von Hippel-Lindau Syndrome. Urologia, 2017, 84, 272-275.	0.7	1
130	<i>Chlamydia trachomatis</i> versus common uropathogens as a cause of chronic bacterial prostatitis: Is there any difference? Results of a prospective parallel-cohort study. Investigative and Clinical Urology, 2017, 58, 460.	2.0	7
131	Chemoprevention., 2017,, 29-41.		O
132	Sentinel lymph Node Detection during Radical Prostatectomy for Prostate Cancer: Current Evidence and Results of Our Experience. Urologia, 2016, 83, 124-129.	0.7	0
133	Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection. Frontiers in Surgery, 2016, 3, 65.	1.4	19
134	H2AX phosphorylation level in peripheral blood mononuclear cells as an eventâ€free survival predictor for bladder cancer. Molecular Carcinogenesis, 2016, 55, 1833-1842.	2.7	15
135	Dietary supplements and prostate cancer prevention. Trends in Urology & Men's Health, 2016, 7, 12-16.	0.4	0
136	The impact of reâ€transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 highâ€grade/Grade 3 bladder cancer treated with bacille Calmette–Guérin. BJU International, 2016, 118, 44-52.	2.5	110
137	Systematic review of lower urinary tract symptoms/benign prostatic hyperplasia surgical treatments on men's ejaculatory function: Time for a bespoke approach?. International Journal of Urology, 2016, 23, 22-35.	1.0	91
138	Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. Journal of Surgical Oncology, 2016, 114, 764-768.	1.7	26
139	Predicting survival in nodeâ€positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multiâ€institutional database. International Journal of Urology, 2016, 23, 1000-1008.	1.0	8
140	A prospective multicentric international study on the surgical outcomes and patients' satisfaction rates of the â€~sliding' technique for endâ€stage Peyronie's disease with severe shortening of the penis and erectile dysfunction. BJU International, 2016, 117, 814-820.	2.5	54
141	Osteoclast-Like Giant Cell Carcinoma Hidden by a Bladder Stone in a Patient With Neurogenic Bladder. Clinical Genitourinary Cancer, 2016, 14, e127-e130.	1.9	2
142	Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol	1.9	11
143	2016;69:60âE"9. European Urology, 2016, 69, e123-e124. Hyperthermia for non-muscle invasive bladder cancer. Expert Review of Anticancer Therapy, 2016, 16, 313-321.	2.4	3
144	Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 234.e13-234.e19.	1.6	15

#	Article	IF	Citations
145	Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase l–II study. World Journal of Urology, 2016, 34, 189-195.	2.2	35
146	EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin. European Urology, 2016, 69, 60-69.	1.9	445
147	Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up. Oncotarget, 2016, 7, 67435-67448.	1.8	55
148	Surgical management of hypogonadic patients with hypotrophic testicles and small penis: a novel, combined technique with an infrapubic approach. Asian Journal of Andrology, 2016, 18, 143.	1.6	0
149	Comment On: Applying Extender Devices in Patients with Penile Dysmorphophobia: Assessment of Tolerability, Efficacy, and Impact on Erectile Function. Journal of Sexual Medicine, 2015, 12, 1248.	0.6	1
150	Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy. European Urology Focus, 2015, 1, 75-81.	3.1	6
151	A randomized doubleâ€blind placebo controlled phase I–II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotionâ€?. Prostate, 2015, 75, 1177-1186.	2.3	55
152	Sexual function after surgical treatment for penile cancer: Which organ-sparing approach gives the best results?. Canadian Urological Association Journal, 2015, 9, 423.	0.6	32
153	Urological Consequences following Renal Transplantation: A Review of the Literature. Urologia, 2015, 82, 211-218.	0.7	6
154	Natural history of surgically treated high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 163.e7-163.e13.	1.6	101
155	Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy. Journal of Urology, 2015, 193, 436-442.	0.4	27
156	Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. Journal of Urology, 2015, 194, 304-309.	0.4	28
157	Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study. European Urology, 2015, 67, 157-164.	1.9	180
158	Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer. European Urology, 2015, 67, 319-325.	1.9	14
159	Prognostic Factors and Risk Groups in T1G3 Non–Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. European Urology, 2015, 67, 74-82.	1.9	190
160	THE STRANGE CASE OF A HAEMATOCELE MISTAKEN FOR A NEOPLASTIC SCROTAL MASS. Canadian Urological Association Journal, 2015, 9, 217.	0.6	6
161	Charlson score to predict overall survival and cancer-related death in elderly patients featuring high-risk prostate cancer Journal of Clinical Oncology, 2015, 33, 84-84.	1.6	0
162	Role of multiparametric magnetic resonance imaging (<scp>MRI</scp>) in focal therapy for prostate cancer: a <scp>D</scp> elphi consensus project. BJU International, 2014, 114, 698-707.	2.5	42

#	Article	IF	CITATIONS
163	Does Sex Reassignment Surgery Induce Cerebral Modifications in MTF Transsexuals?. Journal of Sexual Medicine, 2014, 11, 312-312.	0.6	3
164	<i>C hlamydia</i> â€ <i>t rachomatis</i> Infection Is Related to Premature Ejaculation in Chronic Prostatitis Patients: Results from a Cross-Sectional Study. Journal of Sexual Medicine, 2014, 11, 3085-3092.	0.6	13
165	Shorter Leukocyte Telomere Length Is Independently Associated with Poor Survival in Patients with Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2439-2446.	2.5	29
166	Prognostic Factors of â€~High-Grade' Ta Bladder Cancers according to the WHO 2004 Classification: Are These Equivalent to â€~High-Risk' Non-Muscle-Invasive Bladder Cancer?. Urologia Internationalis, 2014, 92, 136-142.	1.3	22
167	Salvage Radical Prostatectomy in Nonmetastatic Castration-resistant Prostate Cancer Patients Who Received Previous Radiotherapy: A Feasibility Study. European Urology, 2014, 65, 254-255.	1.9	9
168	Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with Mitomycin C in superficial transitional cell carcinoma patients. Cancer Chemotherapy and Pharmacology, 2014, 73, 503-509.	2.3	23
169	Apple consumption is related to better sexual quality of life in young women. Archives of Gynecology and Obstetrics, 2014, 290, 93-98.	1.7	4
170	Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG. European Urology, 2014, 65, 69-76.	1.9	254
171	Concordance and Clinical Significance of Uncommon Variants of Bladder Urothelial Carcinoma in Transurethral Resection and Radical Cystectomy Specimens. Urology, 2014, 84, 1141-1146.	1.0	42
172	Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Current Urology Reports, 2014, 15, 404.	2.2	60
173	DKK-1 in prostate cancer diagnosis and follow up. BMC Clinical Pathology, 2014, 14, 11.	1.8	5
174	Clinical and Cost Effectiveness of Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence Review and Updated Expert Recommendations. European Urology, 2014, 66, 863-871.	1.9	72
175	Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. European Urology, 2014, 66, 577-583.	1.9	76
176	Oral Mucosa Harvest for Urologic Reconstruction. Journal of Craniofacial Surgery, 2014, 25, 604-606.	0.7	8
177	The effect of pathologic T-stage and Gleason score on cancer-specific survival for specimen-confined high-risk prostate cancer Journal of Clinical Oncology, 2014, 32, 114-114.	1.6	O
178	The effect of pathologic T-stage and Gleason score on cancer-specific survival in patients with positive surgical margins after surgery for high-risk prostate cancer Journal of Clinical Oncology, 2014, 32, 140-140.	1.6	0
179	Proteomic identification of Reticulocalbin 1 as potential tumor marker in renal cell carcinoma. Journal of Proteomics, 2013, 91, 385-392.	2.4	37
180	Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma. World Journal of Urology, 2013, 31, 411-415.	2.2	12

#	Article	IF	Citations
181	Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1141-1147.	2.5	3
182	Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance. European Urology, 2013, 63, 462-472.	1.9	382
183	Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World Journal of Urology, 2013, 31, 1029-1036.	2.2	55
184	External validation of the preoperative Karakiewicz nomogram in a large multicentre series of patients with renal cell carcinoma. World Journal of Urology, 2013, 31, 1285-1290.	2.2	4
185	Active surveillance for small renal tumors: Have clinical concerns been addressed so far?. International Journal of Urology, 2013, 20, 356-361.	1.0	8
186	Impact of Age and Comorbidities on Long-term Survival of Patients with High-risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-institutional Competing-risks Analysis. European Urology, 2013, 63, 693-701.	1.9	98
187	1907 LEVEL OF THROMBOUS ACCORDING TO MAYO CLINIC CLASSIFICATION IS AN INDEPENDENT PREDICTOR OF PERIOPERATIVE COMPLICATIONS AND CANCER-RELATED OUTCOME: DATA OF THE IRCVT RCC VENOUS THROMBUS CONSORTIUM. Journal of Urology, 2013, 189, .	0.4	3
188	Management of Superficial Bladder Cancer in Elderly Patients. , 2013, , 231-245.		1
189	Predictors of cancerâ€specific mortality after disease recurrence following radical cystectomy. BJU International, 2013, 111, E30-6.	2.5	77
190	Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: What does an aborted trial tell us?. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 671-675.	1.6	2
191	Obesity is Associated with Worse Outcomes in Patients with T1 High Grade Urothelial Carcinoma of the Bladder. Journal of Urology, 2013, 190, 480-486.	0.4	66
192	Prognostic Factors Including Ki-67 and p53 in Bacillus Calmette-Guérin-Treated Non-Muscle-Invasive Bladder Cancer: A Prospective Study. Urologia Internationalis, 2013, 90, 184-190.	1.3	17
193	Polymorphisms in the <i>XRCC1 </i> gene modify survival of bladder cancer patients treated with chemotherapy. International Journal of Cancer, 2013, 133, 2004-2009.	5.1	27
194	The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (<scp>BPH</scp>). BJU International, 2013, 112, 432-441.	2.5	211
195	Clinical Judgment Versus Biomarker Prostate Cancer Gene 3: Which Is Best When Determining the Need for Repeat Prostate Biopsy?. Urology, 2013, 81, 998-1004.	1.0	27
196	The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guérin Instillation Therapy on the Quality of Life in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Prospective, Randomized, Phase II Trial. Journal of Urology, 2013, 190, 857-862.	0.4	58
197	Genitourinary Fever in Adults. , 2013, , 89-96.		0
198	May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy?. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1955-1960.	2.5	9

#	Article	IF	CITATIONS
199	Leiomyomata of the genitourinary tract: A case series from the "rare urological neoplasm―registry. Scandinavian Journal of Urology, 2013, 47, 158-162.	1.0	9
200	A Rare Case of Primary Mantle Cell Lymphoma of the Prostate: Clinical Aspects and Open Problems. Urologia, 2013, 80, 247-250.	0.7	5
201	Results of surgery for high-risk prostate cancer. Current Opinion in Urology, 2013, 23, 342-348.	1.8	20
202	The Impact of Prior TURP on Radical Prostatectomy Surgical Margins: A Multicenter Analysis. Urologia Internationalis, 2013, 91, 62-68.	1.3	6
203	Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: Profile comparison. International Journal of Urology, 2013, 20, 971-978.	1.0	50
204	Gross (Visible) Hematuria., 2013,, 67-73.		0
205	Microscopic (Non-visible) Hematuria., 2013,, 195-199.		O
206	Female Dysuria/Urinary Tract Infection. , 2013, , 113-121.		0
207	Flank Pain/Renal Colic., 2013,, 3-11.		0
208	Renal Mass., 2013,, 175-181.		0
209	The Role of Adjuvant Hormonal Treatment after Surgery for Localized High-Risk Prostate Cancer: Results of a Matched Multiinstitutional Analysis. Advances in Urology, 2012, 2012, 1-6.	1.3	8
210	Adherence to Guidelines among Italian Urologists on Imaging Preoperative Staging of Low-Risk Prostate Cancer: Results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy) Tj ETQq0 0 0 rg	gBTi/Øverl	ock1010 Tf 50 2
211	Radical prostatectomy in very high-risk localized prostate cancer: Long-term outcomes and outcome predictors. Scandinavian Journal of Urology and Nephrology, 2012, 46, 164-171.	1.4	37
212	Costs in Surgical Techniques for Radical Prostatectomy: A Review of the Current State. Urologia Internationalis, 2012, 88, 1-5.	1.3	3
213	Sense and Nonsense of an Extended Pelvic Lymph Node Dissection in Prostate Cancer. Advances in Urology, 2012, 2012, 1-6.	1.3	14
214	Microwave-induced thermoablation with Amica-probe is a safe and reproducible method to treat solid renal masses: Results from a phase I study. Oncology Reports, 2012, 28, 1243-1248.	2.6	15
215	Outcome Predictors of Radical Prostatectomy Followed by Adjuvant Androgen Deprivation in Patients with Clinical High Risk Prostate Cancer and pT3 Surgical Margin Positive Disease. Journal of Urology, 2012, 188, 84-90.	0.4	28
216	Vasogenic erectile dysfunction Topiramate-induced. Clinical Neurology and Neurosurgery, 2012, 114, 70-71.	1.4	20

#	Article	IF	Citations
217	Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion. World Journal of Urology, 2012, 30, 251-256.	2.2	14
218	Identifying the Best Candidate for Radical Prostatectomy Among Patients with High-Risk Prostate Cancer. European Urology, 2012, 61, 584-592.	1.9	112
219	Debulking surgery in the setting of very highâ€risk prostate cancer scenarios. BJU International, 2012, 110, E192-8.	2.5	29
220	Does kidney transplantation onto the external iliac artery affect the haemodynamic parameters of the cavernosal arteries? Asian Journal of Andrology, 2012, 14, 621-625.	1.6	9
221	Retroperitoneal Laparoscopic Kidney Biopsy: Technical Tips for a Minimally Invasive Approach. Journal of Endourology, 2011, 25, 1639-1642.	2.1	9
222	Clinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions. Journal of Urology, 2011, 185, 2119-2125.	0.4	136
223	Adrenal Ganglioneuroma with Multifocal Retroperitoneal Extension: A Challenging Diagnosis. Scientific World Journal, The, 2011, 11, 1548-1553.	2.1	14
224	Nonâ€invasive methods of penile lengthening: fact or fiction?. BJU International, 2011, 107, 1278-1282.	2.5	28
225	ADVICE ON THE COUNSELING OF PATIENTS SEEKING TREATMENT FOR SHORT PENIS. BJU International, 2011, 108, 1039-1040.	2.5	3
226	Factors predicting continence recovery 1â€fmonth after radical prostatectomy: Results of a multicenter survey. International Journal of Urology, 2011, 18, 700-708.	1.0	38
227	Genital <i>Chlamydia trachomatis</i> Infection is Related to Poor Sexual Quality of Life in Young Sexually Active Women. Journal of Sexual Medicine, 2011, 8, 1131-1137.	0.6	10
228	Patients' Desire to Preserve Sexual Activity and Final Decision for a Nerve-Sparing Approach: Results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) Study. Journal of Sexual Medicine, 2011, 8, 1495-1502.	0.6	13
229	Prostatectomy restores the maturation competence of blood dendritic cell precursors and reverses the abnormal expansion of regulatory T lymphocytes. Prostate, 2011, 71, 344-352.	2.3	8
230	Pathological Features and Adverse Prognosis of a Contemporary Series of Neuroendocrine Bladder Tumours. Urologia Internationalis, 2011, 86, 185-190.	1.3	4
231	Are Referral Centers for Non-Muscle-Invasive Bladder Cancer Compliant to EAU Guidelines? A Report from the Vesical Antiblastic Therapy Italian Study. Urologia Internationalis, 2011, 86, 19-24.	1.3	27
232	Can Gemcitabine Instillation Ablate Solitary Low-Risk Non-Muscle-Invasive Bladder Cancer? Results of a Phase II Marker Lesion Study. Urologia Internationalis, 2011, 87, 470-474.	1.3	7
233	The Role of Bacillus Calmette-Guérin in the Treatment of Non–Muscle-Invasive Bladder Cancer. European Urology, 2010, 57, 410-429.	1.9	160
234	Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients. European Urology, 2010, 58, 1-7.	1.9	140

#	Article	IF	Citations
235	Reply to Endre Zoltan Neulander and Zev Wejsmanâ∈™s Letter to the Editor re: Martin Spahn, Steven Joniau, Paolo Gontero, et al. Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients. Eur Urol 2010;58:1‰7. European Urology, 2010, 58, e37-e38.	1.9	0
236	External Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome. European Urology, 2010, 58, 727-732.	1.9	96
237	Efficacy and Safety of Tadalafil 20mg on Demand vs. Tadalafil 5mg Once-a-Day in the Treatment of Post-Radiotherapy Erectile Dysfunction in Prostate Cancer Men: A Randomized Phase II Trial. Journal of Sexual Medicine, 2010, 7, 2851-2859.	0.6	28
238	<i>In vivo</i> microwaveâ€induced porcine kidney thermoablation: results and perspectives from a pilot study of a new probe. BJU International, 2010, 106, 1817-1821.	2.5	24
239	Pharmacokinetic study to optimize the intravesical administration of gemcitabine. BJU International, 2010, 106, 1652-1656.	2.5	15
240	Kidney Radiofrequency Ablation for Small Renal Tumors: Oncologic Efficacy. Journal of Endourology, 2010, 24, 721-728.	2.1	17
241	Primary bladder phaeochromocytoma diagnosed by a vet. Scandinavian Journal of Urology and Nephrology, 2010, 44, 186-189.	1.4	3
242	Ablative therapies in the treatment of small renal tumors: How far from standard of care?. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 251-259.	1.6	12
243	Fatal Haematuria in a Patient with an Orthotopic Neobladder and Chronic Liver Failure. Urologia Internationalis, 2009, 83, 368-369.	1.3	9
244	Use of Penile Extender Device in the Treatment of Penile Curvature as a Result of Peyronie's Disease. Results of a Phase II Prospective Study. Journal of Sexual Medicine, 2009, 6, 558-566.	0.6	108
245	Regular Moderate Intake of Red Wine is Linked to a Better Women's Sexual Health. Journal of Sexual Medicine, 2009, 6, 2772-2777.	0.6	40
246	Editorial Comment on: Randomized Phase II Trial Evaluation of Erectile Function after Attempted Unilateral Cavernous Nerve-Sparing Retropubic Radical Prostatectomy With Versus Without Unilateral Sural Nerve Grafting for Clinically Localized Prostate Cancer. European Urology, 2009, 55, 1144.	1.9	0
247	Multipathogenetic Origin of a Pelvic Mass. European Urology, 2009, 55, 1224-1228.	1.9	0
248	The Motion: Radiotherapy for Prostate Cancer Preserves Sexual Function to a Greater Extent Than Nerve Sparing Radical Prostatectomy. European Urology, 2009, 56, 212-214.	1.9	8
249	A pilot phase-II prospective study to test the â€~efficacy' and tolerability of a penile-extender device in the treatment of â€~short penis'. BJU International, 2009, 103, 793-797.	2.5	51
250	HIGHâ€GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA AND ATYPICAL SMALL ACINAR PROLIFERATION: IS REPEAT BIOPSY STILL NECESSARY?. BJU International, 2009, 104, 1554-1556.	2.5	13
251	Prognostic factors in a prospective series of papillary renal cell carcinoma. BJU International, 2008, 102, 697-702.	2.5	39
252	Morbidity and Quality of Life in Elderly Patients Receiving Ileal Conduit or Orthotopic Neobladder After Radical Cystectomy for Invasive Bladder Cancer. Urology, 2008, 71, 919-923.	1.0	145

#	Article	IF	CITATIONS
253	An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. European Journal of Cancer, 2008, 44, 2418-2424.	2.8	370
254	Primary adenocarcinoma of the rete testis: Diagnostic problems and therapeutic dilemmas. Scandinavian Journal of Urology and Nephrology, 2008, 42, 83-85.	1.4	10
255	Intravesical Gemcitabine: State of the Art. European Urology Supplements, 2007, 6, 809-815.	0.1	3
256	Adjustable Continence Therapy for the treatment of male stress urinary incontinence: A single-centre study. Scandinavian Journal of Urology and Nephrology, 2007, 41, 324-328.	1.4	51
257	Prevalence, Incidence Estimation, Risk Factors and Characterization of Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Urological Hospital Outpatients in Italy: Results of a Multicenter Case-Control Observational Study. Journal of Urology, 2007, 178, 2411-2415.	0.4	149
258	New Insights Into the Pathogenesis of Penile Shortening After Radical Prostatectomy and the Role of Postoperative Sexual Function. Journal of Urology, 2007, 178, 602-607.	0.4	92
259	CRITICAL ISSUES IN CURRENT COMPARATIVE AND COST ANALYSES BETWEEN RETROPUBIC AND ROBOTIC RADICAL PROSTATECTOMY. BJU International, 2007, 101, 071008070648019-???.	2.5	21
260	Is Radical Prostatectomy Feasible in All Cases of Locally Advanced Non-Bone Metastatic Prostate Cancer? Results of a Single-Institution Study. European Urology, 2007, 51, 922-930.	1.9	62
261	Finasteride 5mg and Sexual Side Effects: How Many of these are Related to a Nocebo Phenomenon?. Journal of Sexual Medicine, 2007, 4, 1708-1712.	0.6	246
262	Male and Female Sexual Dysfunction (SD) after Radical Pelvic Urological Surgery. Scientific World Journal, The, 2006, 6, 2302-2314.	2.1	9
263	Alfuzosin (10mg) Does Not Affect Blood Pressure in Young Healthy Men. European Urology, 2006, 50, 1292-1298.	1.9	5
264	Idiopathic short penis: myth or reality?. BJU International, 2005, 95, 8-9.	2.5	16
265	A prospective evaluation of efficacy and compliance with a multistep treatment approach for erectile dysfunction in patients after non-nerve sparing radical prostatectomy. BJU International, 2005, 95, 359-365.	2.5	47
266	Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. BJU International, 2005, 96, 970-976.	2.5	24
267	Sacral Neuromodulation for Urinary Retention in a Kidney-Transplant Patient. Urologia Internationalis, 2005, 75, 187-188.	1.3	7
268	Inguinal versus subinguinal varicocele vein ligation using magnifying loupe under local anesthesia: Which technique is preferable in clinical practice?. Urology, 2005, 66, 1075-1079.	1.0	49
269	Upper Urinary Tract Complications in Pregnant Women with an Ileal ConduitLessons Learned from Two Cases. Scandinavian Journal of Urology and Nephrology, 2004, 38, 523-524.	1.4	4
270	Are the current conservative treatments for peyronie's disease evidence-based?. BJU International, 2004, 94, 3-4.	2.5	1

#	Article	IF	CITATION
271	Metastasis Markers in Bladder Cancer: A Review of the Literature and Clinical Considerations. European Urology, 2004, 46, 296-311.	1.9	66
272	Phase II Study to Investigate the Ablative Efficacy of Intravesical Administration of Gemcitabine in Intermediate-Risk Superficial Bladder Cancer (SBC). European Urology, 2004, 46, 339-343.	1.9	76
273	Re: A Prospective Study Measuring Penile Length in Men Treated With Radical Prostatectomy for Prostate Cancer. Journal of Urology, 2004, 171, 359-360.	0.4	O
274	Is There an Optimal Time for Intracavernous Prostaglandin E1 Rehabilitation Following Nonnerve Sparing Radical Prostatectomy? Results From a Hemodynamic Prospective Study. Journal of Urology, 2003, 169, 2166-2169.	0.4	99
275	Pathological Findings of Penile Fractures and Their Surgical Management. Urologia Internationalis, 2003, 71, 77-82.	1.3	20
276	Bladder tumor antigen assay as compared to voided urine cytology in the diagnosis of bladder cancer. Clinica Chimica Acta, 2001, 305, 47-53.	1.1	16
277	The genetic alterations in the oncogenic pathway of transitional cell carcinoma of the bladder and its prognostic value. Urological Research, 2001, 29, 377-387.	1.5	8